• Viehbacher: Diet Pill Guidance Needed To Ensure Investment

    Speaking to Reuters on Thursday, Pharmaceutical Research and Manufacturers of America (PhRMA) Chairman and Sanofi SA CEO Chris Viehbacher said that the US Food and Drug Administration (FDA) needs to offer more guidance on their risk and benefit determinations for diet pills. "To make sure we're not ignoring unmet needs in primary care, we need a lot more clarity around the risk-benefit so there's predictability when we invest in these products," said Viehbacher. FDA...
  • Risk Aversion in Indian Deal-Making the Result of Regulatory Compliance Concerns

    Global pharmaceutical companies-and in particular western pharmaceutical companies-are shying away from buying or partnering with Indian generics manufacturers because of quality and compliance issues , write WSJ journalists Namrate Nandakumar and C.H. Unnikrishnan. Companies, including Pfizer, Sanofi-Aventis, and Daiichi Sankyo have been hit with fines, delays, or both after acquiring or partnering with Indian generics manufactures.  Daiichi Sankyo, for instance...